Bryce Point Capital, LLC Supernus Pharmaceuticals, Inc. Transaction History
Bryce Point Capital, LLC
- $81.9 Billion
- Q3 2025
A detailed history of Bryce Point Capital, LLC transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Bryce Point Capital, LLC holds 5,619 shares of SUPN stock, worth $252,855. This represents 0.33% of its overall portfolio holdings.
Number of Shares
5,619Holding current value
$252,855% of portfolio
0.33%Shares
1 transactions
Others Institutions Holding SUPN
# of Institutions
332Shares Held
58.4MCall Options Held
28.8KPut Options Held
0-
Black Rock Inc. New York, NY10.4MShares$468 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.04MShares$272 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY4.81MShares$217 Million2.66% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3MShares$135 Million0.03% of portfolio
-
Macquarie Group LTD Australia, C32.53MShares$114 Million0.14% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $2.41B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...